Navigation Links
Dendreon Reports First Quarter 2011 Financial Results
Date:5/2/2011

DATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)Three Months Ended
March 31,20112010(unaudited)Revenue

$28,061$21Cost of revenue

18,338—Gross profit

9,72321Operating expenses:Research and development

17,60929,414Selling, general and administrative

95,28928,218Total operating expenses

112,89857,632Loss from operations

(103,175)(57,611)Interest income

400278Interest expense

(8,993)(314)(Loss) gain from valuation of warrant liability

—(68,083)Net loss

($111,768)($125,730)Basic and diluted net loss per share

($0.77)($0.96)Shares used in computation of basic anddiluted net loss per share

145,494131,456March 31,December 31,20112010Balance Sheet Data:Cash and cash equivalents

$555,297$132,995Short-term investments

157,094121,796Long-term investments

66,63022,505Trade accounts receivable

16,86412,679Prepaid antigen costs

24,32517,656Inventory

38,87230,928Total  assets

1,130,688603,953Convertible senior notes due 2016

491,424—Convertible senior subordinated notes due 2014

27,68527,685Total stockholders' equity

526,451492,774DENDREON CORPORATIONRECONCILIATION OF GAAP TO NON-GAAP NET LOSS (in thousands, except per share amounts)Three Months Ended
March 31,20112010(unaudited)GAAP net loss

($111,768)($125,730)Non-GAAP adjustments:Depreciation and amortization expense

7,4092,465Stock-based compensation expense

14,6767,070Imputed interest related to the convertible
senior notes due 2016

4,300—Non-GAAP net loss

($85,383)($116,195)Non-GAAP net loss per share- basic and diluted

($0.59)($0.88)Shares used in computation of basic anddiluted net loss per share

145,494131,456The above table provides certain non-GAAP financial measures that include adjustments to GAAP figures. Dendreon believes that these non-GAAP fina
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon to Host Conference Call on May 2, 2011 to Announce First Quarter 2011 Financial Results
2. Dendreon Reports Fourth Quarter and 2010 Year End Financial Results
3. Dendreon Announces Webcast Presentations at Four Upcoming Conferences
4. Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
5. Dendreon to Host Conference Call on March 1st to Announce Fourth Quarter and Year-End Financial Results
6. Dendreon Announces Pricing of $540 Million Convertible Senior Notes Due 2016
7. Dendreon Announces Plans to Seek Marketing Authorization for PROVENGE in Europe
8. Dendreon to Host Conference Call to Provide Updates on U.S. Commercialization Progress, European Strategy for PROVENGE, and Pipeline Progress
9. Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence
10. Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility
11. Dendreon to Host Conference Call on November 3rd to Announce Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... 2015 , ... R-Biopharm is proud to announce the RIDASCREEN® ... foods, has been accepted by AOAC International as Official First Action method. The ... Products by R5 Competitive ELISA,” based on a specific monoclonal antibody to potentially ...
(Date:7/30/2015)... Mass. , July 30, 2015   ... solutions for the interpretation and analysis of genomic ... Matthew Fischer has joined the company as ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... capabilities to integrate, interpret, analyze and explore complex ...
(Date:7/30/2015)... 2015 According to a new ... Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract ... Trial), by End Users - Global Forecast to 2020", ... reach USD 2,107.99 million by 2020 from USD 1,034.93 ... Browse more than 75 ...
(Date:7/30/2015)...   Senomyx , Inc. (NASDAQ: SNMX ), ... discover, develop, and commercialize novel flavor ingredients for the ... results for the second quarter 2015. ... on track to achieve our commercial and financial goals," ... the Company. "Since our last quarterly earnings report, our ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
... Nov. 21, 2011 Double Eagle Holdings, Ltd. (OTCQB: DROP), ... announced last week a partnership with golf superstar Tiger Woods ... his bag. Woods and CEO of FUSE Science Adam Adler ... partnership on CNBC today Monday, November 21, at 12:30 p.m. ...
... The report " Leukemia Therapeutics Market (Acute/Chronic ... Global Market Forecast (2010 - 2020) " ... opportunities in North America, & Europe. ... Leukemia Therapeutics Market (Acute/Chronic Lymphocytic Leukemia & Acute/Chronic Myeloid ...
... 2011 - A research group from RIKEN, the University ... today announced that research results obtained using the "K ... at SC11, the International Conference for High Performance Computing, ... November 17 (US Pacific Standard Time). The award-winning ...
Cached Biology Technology:Tiger Woods Gives Exclusive First Interview Since POWERED by FUSE Announcement! 2MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020 2MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020 3'K computer' research results awarded ACM Gordon Bell Prize 2
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/7/2015)... , July 7, 2015  Based on ... Frost & Sullivan recognizes Credence ID, LLC with ... Entrepreneurial Company of the Year Award. Credence ID ... aid in its mission of offering enrollment and ... globally. As Credence ID was formed by experts ...
(Date:6/30/2015)... 2015 To bolster its efforts and commitment to ... today the addition of two new team members. ... and David Raviv will act as head of ... commitment to providing the most secure solutions for the enterprise ... Layer 7 Technologies, a provider of security and management products, ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... Studies show 97 percent of American adults get less ... the minimum recommended amount based on federal guidelines. New ... traits may predispose people to being more or less ... professor in the MU College of Veterinary Medicine, along ...
... Barcelona have discovered new clues about past rapid climate ... journal Nature Geoscience , concludes that oceanographic reorganisations ... airborne dust in the Southern Ocean and this connection ... atmospheric carbon dioxide levels, an important component in the ...
... A team of researchers, led by Marc Freeman, PhD, an ... associate professor of neurobiology at the University of Massachusetts Medical ... Drosophila melanogaster that, when mutant, blocks the self-destruction of ... diseases, such as amyotrophic lateral sclerosis (ALS). A ...
Cached Biology News:Couch potatoes may be genetically predisposed to being lazy, MU study finds 2Rapid climate change and the role of the Southern Ocean 2A fly mutation suggests a new route for tackling ALS 2A fly mutation suggests a new route for tackling ALS 3
PKC (pSer345), phospho-specific...
MAB3246 recognizes the neuro-endocrine specific protein (NSP) C....
Anti-ADAMTS-4, disintegrin-like domain Immunogen: Synthetic peptide - KLH conjugated Available Date: 38569...
Rat integrin a6b1, mainly associated with epithelial cells. Does not react with rat fibroblasts....
Biology Products: